Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Consensus Target Price of $46.89

Key Points

• Analysts remain broadly positive: Tyra Biosciences has a “Moderate Buy” consensus from 14 firms, with 12 buy ratings, and an average 12-month price target of $46.89 versus a recent price of $22.41.
• Forecasts point to narrowing losses: HC Wainwright raised its future EPS estimates, while maintaining a Buy rating and $29 target. However, Oppenheimer lowered its target to $40 from $50, highlighting differing analyst expectations.
• Risks remain significant: Tyra continues to operate at a loss and recently missed quarterly EPS expectations. As a clinical-stage biotechnology company, its valuation remains highly dependent on clinical progress, execution and funding needs.

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fourteen research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and twelve have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $46.89.

TYRA has been the topic of a number of recent research reports. Jefferies Financial Group reaffirmed a "buy" rating and issued a $42.00 target price on shares of Tyra Biosciences in a report on Wednesday, August 5th. Cantor Fitzgerald reissued an "overweight" rating on shares of Tyra Biosciences in a report on Thursday, September 10th. Oppenheimer restated an "outperform" rating and issued a $40.00 price target (down from $50.00) on shares of Tyra Biosciences in a research report on Tuesday. Wedbush reaffirmed an "outperform" rating and issued a $53.00 price objective on shares of Tyra Biosciences in a research note on Thursday, September 10th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $56.00 price objective on shares of Tyra Biosciences in a research report on Tuesday, September 8th.

Tyra Biosciences News Roundup

Here are the key news stories impacting Tyra Biosciences this week:

• Positive Sentiment: HC Wainwright improved its forecasts: The firm raised its FY2026 EPS estimate to a loss of $2.60 from $2.86 and its FY2027 estimate to a loss of $2.27 from $3.20. Quarterly estimates for Q4 2026 and every quarter of 2027 were also raised, suggesting expectations for narrower losses and improving operating performance.
• Positive Sentiment: Buy rating and target remain intact: HC Wainwright reiterated its Buy rating and $29 price objective. That target is above the stock’s recently reported trading level, offering potential upside if the company meets the improved forecasts.
• Neutral Sentiment: Short-interest data shows little measurable bearish positioning: Reported short interest as of September 24 was 0 shares, with a 0.0-day short-interest ratio based on average volume of roughly 1.74 million shares. While the report describes a large increase, the stated figures indicate no meaningful short-selling pressure; investors should treat the data cautiously because the figures appear inconsistent.
• Negative Sentiment: Tyra remains unprofitable: The revised projections still anticipate losses, including a consensus loss of $2.73 per share for the current year. The company’s continued dependence on future clinical and development progress means valuation remains sensitive to execution, funding needs and trial-related news.

Institutional Trading of Tyra Biosciences

Several institutional investors and hedge funds have recently modified their holdings of TYRA. Tidal Investments LLC purchased a new position in shares of Tyra Biosciences during the 2nd quarter valued at $943,000. WINTON GROUP Ltd purchased a new stake in Tyra Biosciences in the 2nd quarter worth $537,000. Engineers Gate Manager LP bought a new stake in Tyra Biosciences during the second quarter valued at about $1,021,000. Squarepoint Ops LLC raised its holdings in Tyra Biosciences by 211.3% during the second quarter. Squarepoint Ops LLC now owns 63,805 shares of the company's stock valued at $2,038,000 after acquiring an additional 43,311 shares during the period. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of Tyra Biosciences in the second quarter valued at about $334,000. 84.14% of the stock is currently owned by institutional investors.

Tyra Biosciences Trading Down 3.5%

TYRA opened at $22.41 on Friday. The company's 50 day moving average is $27.01 and its 200 day moving average is $31.24. The company has a market cap of $1.34 billion, a price-to-earnings ratio of -9.34 and a beta of 0.73. Tyra Biosciences has a 12-month low of $12.40 and a 12-month high of $40.65.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.04). As a group, analysts predict that Tyra Biosciences will post -2.68 EPS for the current fiscal year.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for diseases with limited treatment options. The company uses its proprietary SNÅP platform to design small-molecule therapies intended to selectively target disease-driving genetic alterations while addressing resistance mechanisms that can reduce the effectiveness of existing treatments.

Tyra's lead programs are directed at fibroblast growth factor receptor (FGFR) biology. TYRA-300 is an oral, selective FGFR3 inhibitor being developed for conditions including FGFR3-altered urothelial cancer and achondroplasia, a genetic skeletal disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.